Physician profile
Thomas M Jordan
NPI 1194821850
$4,759.59
in general payments reported to CMS, 2019-2025
24 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $210 · 2021: $826 · 2022: $349 · 2023: $1,030 · 2024: $874 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $863.02 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $658.78 | 2019-2021 | |
| Boston Scientific Corporation | $463.90 | 2021-2024 | Watchman Access System, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $447.08 | 2022-2025 | Camzyos |
| Amgen INC. | $378.73 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $375.89 | 2019-2023 | Lifevest |
| Abbott Laboratories | $270.00 | 2019-2024 | Mitraclip |
| Medtronic Vascular, INC. | $178.08 | 2019-2020 | |
| Medtronic, INC. | $153.71 | 2023 | Micra |
| Janssen Scientific Affairs, LLC | $132.80 | 2024 | Xarelto |
| Pfizer INC. | $129.08 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $124.79 | 2021-2023 | Verquvo |
| Astellas Pharma US INC | $121.32 | 2021 | |
| Nuwellis, INC. | $115.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $82.93 | 2019-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $54.41 | 2021-2024 | Nexletol |
| Novo Nordisk INC | $53.86 | 2021 | |
| Amarin Pharma, INC. | $38.08 | 2019-2020 | |
| Edwards Lifesciences Corporation | $25.76 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lantheus Medical Imaging, INC. | $23.50 | 2024 | |
| Chiesi USA, INC. | $21.61 | 2023 | Kengreal, Cleviprex |
| Phadia US INC. | $16.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.64 | 2019 | |
| Baxter Healthcare | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.